Overview

This trial is active, not recruiting.

Condition melanoma
Treatment imm-101
Phase phase 1/phase 2
Sponsor Immodulon Therapeutics Ltd
Start date February 2012
End date December 2018
Trial size 12 participants
Trial identifier NCT01559818, IMM-101-008

Summary

Patients who were previously enrolled in Study IMM-101-001 and who provide informed consent will be eligible to participate in this study.

Once eligibility is confirmed, a full medical history covering the period from their completion of Study IMM-101-001 to date will be taken.

The treatment regimen with IMM-101 will be one dose given every 4 weeks or as close to this interval as permitted due to practical or logistic considerations. The dose interval may be modified at the discretion of the Investigator provided the minimum period between doses in no less than 14 days.

The overall objective is to determine the long term safety profile of IMM-101 administered intradermally for extended use.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking no masking
Arm
(Experimental)
IMM-101 1.0 mg administered intradermally
imm-101 Heat-killed whole cell M. obuense
IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.

Primary Outcomes

Measure
Safety
time frame: 36 months

Secondary Outcomes

Measure
Efficacy
time frame: 36 months
Exploratory
time frame: 36 months

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - Patient was previously enrolled in Study IMM 101 001 - Patient gives consent to make their disease and treatment history for the intervening period between their completion of Study IMM-101-001 and enrollment in this study available to the Sponsor - Patient gives signed informed consent for participation in the study Exclusion Criteria: - Female patient of child-bearing potential who is not, in the opinion of the Investigator, using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]). Those patients that utilise hormonal contraceptives must have used the same method for at least three months before additional barrier contraception (as described above) is discontinued from being used concomitantly with the hormonal contraception. - Patient of non-child-bearing potential are defined as having 12 month amenorrhoea or are surgically sterile. - Female patient who is pregnant, breast feeding or planning a pregnancy during the course of the study. A pre-treatment urine pregnancy test measuring human chorionic gonadotrophin (hCG) must be negative. - Patient is unable or unwilling to comply with the protocol.

Additional Information

Official title An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001
Principal investigator Angus Dalgleish, Professor
Description This is an open-label long term follow up study. The study will consist of two phases: 1. Screening and enrolment Patients, who provide informed consent, will participate in a screening period of up to 28 days to establish eligibility. Once eligibility is confirmed a full disease and treatment history covering the period from their completion of Study IMM-101 001 to date will be taken. 2. Treatment Patients can receive ongoing treatment every 4 weeks or as close to this interval as permitted due to practical or logistic considerations until death or withdrawal, unless such therapy is contraindicated, the patient does not wish to continue or the study is terminated by the Sponsor. At no point should the elapsed period between IMM-101 doses be less than 14 days. Patients may choose to withdraw from the study at any time and for any reason. IMM-101 should be stopped or the dosing regimen reduced if felt to be necessary by the Investigator and/or patient (e.g., intolerable injection site reactions). In the event of an injection site reaction of Grade 3 and above, and/or if significant ulceration, tenderness or lymphadenopathy is observed, at the discretion of the Investigator, patients may be administered a half dose of the study drug (i.e., a single 0.05 mL intradermal injection of IMM-101) or the timing of the injection may be delayed. If the dosing interval is increased, the patient should still attend the study site for safety assessments preferably every 3 months but, if this is not possible, every 6 months at a minimum. The blood sample for exploratory analysis should continue to be taken every 6 months. Any change in the dose of study drug administered or the frequency of dose administration should be recorded in the patient's case report form (CRF). In the case of withdrawal, separate consent will be sought to allow the continued collection on patient status.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Immodulon Therapeutics Ltd.